Hims House Dr. William Seeds - WTF are peptides? Are they legal? And where does Hims fit in?
12 snips
Aug 27, 2025 
In this engaging discussion, Dr. William Seeds, a board-certified orthopedic surgeon and pioneer in peptide therapy, shares his transformative journey from finance to medicine after a personal tragedy. He delves into the fascinating world of peptides, highlighting their potential as 'magical' drugs and the skepticism they face. The conversation explores the U.S. lag in peptide adoption compared to Europe and Asia, the influence of Big Pharma, and how Hims plans to navigate the legal landscape to introduce innovative peptide products in the coming decade.
AI Snips
Chapters
Transcript
Episode notes
GLP-1s Are Only The Tip Of The Iceberg
- The peptide universe extends far beyond GLP-1s and includes tissue repair, immune modulation, mitochondrial rescue, and growth-hormone axis peptides.
- GLP-1s are pleiotropic and will see uses in cancer, neurodegeneration, bone health, and immune function.
Regulation, Not Science, Slows Progress
- The main barrier to peptide adoption is regulatory and legal, not science; many candidates sit in limbo because they don't fit pharma IP models.
- Thousands of signaling peptides remain uncharted (the 'dark peptidome') because current tools and incentives miss small peptides.
Judge Peptides By Mechanistic Evidence
- Don’t dismiss peptides for lack of large RCTs; review mechanistic studies, preclinical data, and decades of international experience.
- Prioritize evidence-based clinical trials to validate promising peptides rather than relying solely on hype or criticism.